Characterization of the structure and function of a new mitogen-activated protein kinase (p38 beta)

被引:642
|
作者
Jiang, Y
Chen, CH
Li, ZJ
Guo, W
Gegner, JA
Lin, SC
Han, JH
机构
[1] Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA
[2] NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SINGAPORE 117548, SINGAPORE
关键词
D O I
10.1074/jbc.271.30.17920
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mitogen-activated protein (MAP) kinase cascades represent one of the major signal systems used by eukaryotic cells to transduce extracellular signals into cellular responses, Four MAP kinase subgroups have been identified in humans: ERK, JNK (SAPK), ERK5 (BMK), and p38, Here we characterize a new MAP kinase, p38 beta. p38 beta is a 372-amino acid protein most closely related to p38. It contains a TGY dual phosphorylation site, which is required for its kinase activity. Like p38, p38 beta is activated by proinflammatory cytokines and environmental stress. A comparison of events associated with the activation of p38 beta and p38 revealed differences, most notably in the preferred activation of p38 beta by MAP kinase kinase 6 (MKK6), whereas p38 was activated nearly equally by MKK3, MKK4, and MKK6. Moreover, in. vitro and in vivo experiments showed a strong substrate preference by p38 beta for activating transcription factor 2 (ATF2), Enhancement of ATF2-dependent gene expression by p38 beta was similar to 2O-fold greater than that of p38 and other MAP kinases tested, The data reported here suggest that while closely related, p38 beta and p38 may be regulated by differing mechanisms and may exert their actions on separate downstream targets.
引用
收藏
页码:17920 / 17926
页数:7
相关论文
共 50 条
  • [41] The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis
    Schett, G.
    Zwerina, J.
    Firestein, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (07) : 909 - 916
  • [42] p38 mitogen-activated protein kinase inhibitors - Mechanisms and therapeutic potentials
    Lee, JC
    Kassis, S
    Kumar, S
    Badger, A
    Adams, JL
    PHARMACOLOGY & THERAPEUTICS, 1999, 82 (2-3) : 389 - 397
  • [43] Intrathymic signals in thymocytes are mediated by p38 mitogen-activated protein kinase
    Sen, J
    Kapeller, R
    Fragoso, R
    Sen, R
    Zon, LI
    Burakoff, SJ
    JOURNAL OF IMMUNOLOGY, 1996, 156 (12): : 4535 - 4538
  • [44] Increased phosphorylated p38 mitogen-activated protein kinase in COPD Lungs
    Gaffey, Kate
    Reynolds, Sophie
    Plumb, Jonathan
    Kaur, Manminder
    Singh, Dave
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42 (01) : 28 - 41
  • [45] The case for inhibiting p38 mitogen-activated protein kinase in heart failure
    Arabacilar, Pelin
    Marber, Michael
    FRONTIERS IN PHARMACOLOGY, 2015, 6
  • [46] Current Insights of Inhibitors of p38 Mitogen-Activated Protein Kinase in Inflammation
    Awasthi, Archana
    Raju, Mantripragada Bhagavan
    Rahman, Md. Azizur
    MEDICINAL CHEMISTRY, 2021, 17 (06) : 555 - 575
  • [47] Activation of p38 Mitogen-Activated Protein Kinase in Gaucher's Disease
    Kitatani, Kazuyuki
    Wada, Masayuki
    Perry, David
    Usui, Toshinori
    Sun, Ying
    Obeid, Lina M.
    Yaegashi, Nobuo
    Grabowski, Gregory A.
    Hannun, Yusuf A.
    PLOS ONE, 2015, 10 (08):
  • [48] The role of p38α mitogen-activated protein kinase activation in renal fibrosis
    Stambe, C
    Atkins, RC
    Tesch, GH
    Masaki, T
    Schreiner, GF
    Nikolic-Paterson, DJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2004, 15 (02): : 370 - 379
  • [49] Activation of the p38 mitogen-activated protein kinase by type I interferons
    Uddin, S
    Majchrzak, B
    Woodson, J
    Arunkumar, P
    Alsayed, Y
    Pine, R
    Young, PR
    Fish, EN
    Platanias, LC
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (42) : 30127 - 30131
  • [50] p38 mitogen-activated protein kinase: Functions and targeted therapy in diseases
    Zheng, Qinwen
    Li, Shutong
    Wang, Aoxue
    Zhe, Man
    Yang, Panpan
    Wu, Yongya
    Zhao, Min
    Zhu, Yumeng
    Luo, Yi
    Wang, Guan
    Ouyang, Liang
    MEDCOMM-ONCOLOGY, 2023, 2 (03):